Biogen (BUE:BIIB) Long-Term Debt

: ARS2,450,540 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

Biogen's Long-Term Debt for the quarter that ended in Dec. 2023 was ARS2,450,540 Mil.

Biogen's quarterly Long-Term Debt increased from Jun. 2023 (ARS1,508,304 Mil) to Sep. 2023 (ARS2,374,901 Mil) and increased from Sep. 2023 (ARS2,374,901 Mil) to Dec. 2023 (ARS2,450,540 Mil).

Biogen's annual Long-Term Debt increased from Dec. 2021 (ARS633,611 Mil) to Dec. 2022 (ARS1,053,010 Mil) and increased from Dec. 2022 (ARS1,053,010 Mil) to Dec. 2023 (ARS2,450,540 Mil).

Biogen Long-Term Debt Historical Data

The historical data trend for Biogen's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

266,530.48

604,344.13

633,611.25

1,053,009.62

2,450,540.20

Biogen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Debt																1,053,009.62	1,241,147.41	1,508,303.99	2,374,900.75	2,450,540.20

Biogen (BUE:BIIB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Biogen Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Biogen's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.